Synthesis and biological evaluation of substituted acetamide derivatives as potential butyrylcholinestrase inhibitors
Alzheimer’s disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective therapeutic target for AD. A series of new substituted acetamide derivatives were designed, synthesized and evaluated for their ability to inhibit BChE. The bio...
Saved in:
| Published in | Scientific reports Vol. 13; no. 1; p. 4877 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
25.03.2023
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Alzheimer’s disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective therapeutic target for AD. A series of new substituted acetamide derivatives were designed, synthesized and evaluated for their ability to inhibit BChE. The bioassay results revealed that several compounds displayed attractive inhibition against BChE). Among them, compound
8c
exhibited the highest BChE inhibition with IC
50
values of 3.94 μM. Lineweaver Burk plot indicated that
8c
acted as a mixed-type BChE inhibitor. In addition, docking studies confirmed the results obtained through in vitro experiments, and showed that
8c
bound to the catalytic anionic site (CAS) and peripheral anionic site (PAS) of BChE active site. Meanwhile, its ADME parameters were approximated using in silico method. Molecular dynamics simulation studies on the complex of
8c
-BChE were performed, RMSD, RMSF, Rg, SASA, and the number of hydrogen bonds were calculated as well. These results implied that
8c
could serve as appropriate lead molecule for the development of BChE inhibitor. |
|---|---|
| AbstractList | Alzheimer’s disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective therapeutic target for AD. A series of new substituted acetamide derivatives were designed, synthesized and evaluated for their ability to inhibit BChE. The bioassay results revealed that several compounds displayed attractive inhibition against BChE). Among them, compound
8c
exhibited the highest BChE inhibition with IC
50
values of 3.94 μM. Lineweaver Burk plot indicated that
8c
acted as a mixed-type BChE inhibitor. In addition, docking studies confirmed the results obtained through in vitro experiments, and showed that
8c
bound to the catalytic anionic site (CAS) and peripheral anionic site (PAS) of BChE active site. Meanwhile, its ADME parameters were approximated using in silico method. Molecular dynamics simulation studies on the complex of
8c
-BChE were performed, RMSD, RMSF, Rg, SASA, and the number of hydrogen bonds were calculated as well. These results implied that
8c
could serve as appropriate lead molecule for the development of BChE inhibitor. Abstract Alzheimer’s disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective therapeutic target for AD. A series of new substituted acetamide derivatives were designed, synthesized and evaluated for their ability to inhibit BChE. The bioassay results revealed that several compounds displayed attractive inhibition against BChE). Among them, compound 8c exhibited the highest BChE inhibition with IC50 values of 3.94 μM. Lineweaver Burk plot indicated that 8c acted as a mixed-type BChE inhibitor. In addition, docking studies confirmed the results obtained through in vitro experiments, and showed that 8c bound to the catalytic anionic site (CAS) and peripheral anionic site (PAS) of BChE active site. Meanwhile, its ADME parameters were approximated using in silico method. Molecular dynamics simulation studies on the complex of 8c-BChE were performed, RMSD, RMSF, Rg, SASA, and the number of hydrogen bonds were calculated as well. These results implied that 8c could serve as appropriate lead molecule for the development of BChE inhibitor. Alzheimer’s disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective therapeutic target for AD. A series of new substituted acetamide derivatives were designed, synthesized and evaluated for their ability to inhibit BChE. The bioassay results revealed that several compounds displayed attractive inhibition against BChE). Among them, compound 8c exhibited the highest BChE inhibition with IC50 values of 3.94 μM. Lineweaver Burk plot indicated that 8c acted as a mixed-type BChE inhibitor. In addition, docking studies confirmed the results obtained through in vitro experiments, and showed that 8c bound to the catalytic anionic site (CAS) and peripheral anionic site (PAS) of BChE active site. Meanwhile, its ADME parameters were approximated using in silico method. Molecular dynamics simulation studies on the complex of 8c-BChE were performed, RMSD, RMSF, Rg, SASA, and the number of hydrogen bonds were calculated as well. These results implied that 8c could serve as appropriate lead molecule for the development of BChE inhibitor. Abstract Alzheimer’s disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective therapeutic target for AD. A series of new substituted acetamide derivatives were designed, synthesized and evaluated for their ability to inhibit BChE. The bioassay results revealed that several compounds displayed attractive inhibition against BChE). Among them, compound 8c exhibited the highest BChE inhibition with IC 50 values of 3.94 μM. Lineweaver Burk plot indicated that 8c acted as a mixed-type BChE inhibitor. In addition, docking studies confirmed the results obtained through in vitro experiments, and showed that 8c bound to the catalytic anionic site (CAS) and peripheral anionic site (PAS) of BChE active site. Meanwhile, its ADME parameters were approximated using in silico method. Molecular dynamics simulation studies on the complex of 8c -BChE were performed, RMSD, RMSF, Rg, SASA, and the number of hydrogen bonds were calculated as well. These results implied that 8c could serve as appropriate lead molecule for the development of BChE inhibitor. Alzheimer's disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective therapeutic target for AD. A series of new substituted acetamide derivatives were designed, synthesized and evaluated for their ability to inhibit BChE. The bioassay results revealed that several compounds displayed attractive inhibition against BChE). Among them, compound 8c exhibited the highest BChE inhibition with IC values of 3.94 μM. Lineweaver Burk plot indicated that 8c acted as a mixed-type BChE inhibitor. In addition, docking studies confirmed the results obtained through in vitro experiments, and showed that 8c bound to the catalytic anionic site (CAS) and peripheral anionic site (PAS) of BChE active site. Meanwhile, its ADME parameters were approximated using in silico method. Molecular dynamics simulation studies on the complex of 8c-BChE were performed, RMSD, RMSF, Rg, SASA, and the number of hydrogen bonds were calculated as well. These results implied that 8c could serve as appropriate lead molecule for the development of BChE inhibitor. |
| ArticleNumber | 4877 |
| Author | Yu, Dehong Liu, Zerong Li, Yanfang Yang, Can Chen, Gang Liu, Yi Lu, Tao Li, Lizi |
| Author_xml | – sequence: 1 givenname: Dehong surname: Yu fullname: Yu, Dehong organization: School of Chemical Engineering, Sichuan University – sequence: 2 givenname: Can surname: Yang fullname: Yang, Can organization: School of Chemical Engineering, Sichuan University – sequence: 3 givenname: Yi surname: Liu fullname: Liu, Yi organization: School of Chemical Engineering, Sichuan University – sequence: 4 givenname: Tao surname: Lu fullname: Lu, Tao organization: School of Chemical Engineering, Sichuan University – sequence: 5 givenname: Lizi surname: Li fullname: Li, Lizi organization: School of Chemical Engineering, Sichuan University – sequence: 6 givenname: Gang surname: Chen fullname: Chen, Gang organization: Central Nervous System Drug Key Laboratory of Sichuan Province, Sichuan Credit Pharmaceutical CO., Ltd – sequence: 7 givenname: Zerong surname: Liu fullname: Liu, Zerong organization: Central Nervous System Drug Key Laboratory of Sichuan Province, Sichuan Credit Pharmaceutical CO., Ltd – sequence: 8 givenname: Yanfang surname: Li fullname: Li, Yanfang email: lyf471@vip.163.com organization: School of Chemical Engineering, Sichuan University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36966194$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1vEzEQhleoiH7QP8ABrcSFy4K_1h8nhCqglSpxAM6W154kjhw72N5I-fd1mlJaDvgylueZd2as97w7iSlC173B6ANGVH4sDI9KDojQgWLJ1DC-6M4IYuNAKCEnT-6n3WUpa9TOSBTD6lV3SrniHCt21s0_9rGuoPjSm-j6yaeQlt6a0MPOhNlUn2KfFn2Zp1J9nSu43lioZuMd9A6y3zVmB6289NtUIVbfiqe57vM-2FUKPkKp2RTofVz5ydeUy-vu5cKEApcP8aL79fXLz6vr4fb7t5urz7eDHRmug0SYUisEFhIpSVuk1FEwhDJMKHKMWwnOciuMpWZigCYu1Eix4U6hhlx0N0ddl8xab7PfmLzXyXh9_5DyUptcvQ2gLUfT5ISS3AiGMTECjYgqDjByNo2uaX06am3nadO6tk2zCc9En2eiX-ll2mmMmo4Uoim8f1DI6ffcfkVvfLEQgomQ5qKJUJhyKeQBffcPuk5zju2vDhTiirXhGkWOlM2plAyLx2kw0geX6KNLdHOJvneJHlvR26d7PJb88UQD6BEoLRWXkP_2_o_sHdqjy6E |
| CitedBy_id | crossref_primary_10_1007_s10593_024_03298_z crossref_primary_10_1016_j_bmcl_2023_129392 crossref_primary_10_1016_j_ijbiomac_2024_129286 crossref_primary_10_1038_s41598_024_66424_z crossref_primary_10_55971_EJLS_1374823 |
| Cites_doi | 10.1002/cne.10751 10.1085/jgp.200409111 10.1021/bi00096a018 10.1021/bi300955k 10.1021/ja01318a036 10.1602/neurorx.2.4.541 10.1136/jnnp.66.2.137 10.1016/j.ejmech.2022.114729 10.1016/j.pneurobio.2018.12.006 10.1124/jpet.107.133330 10.1016/j.phymed.2018.09.199 10.1016/j.ejmech.2017.07.070 10.1007/s11010-010-0563-x 10.1021/bi971425+ 10.3389/fphar.2018.00923 10.1016/j.cca.2006.11.005 10.1016/j.ejmech.2016.10.060 10.1007/978-1-61779-588-6_10 10.1016/j.drudis.2019.03.015 10.1016/j.ejmech.2018.01.007 10.1016/j.jmgm.2021.108077 10.1039/D2NJ00115B 10.1073/pnas.0508575102 10.1080/13543776.2017.1272571 10.1016/j.bbr.2011.07.035 10.4155/fmc-2020-0325 10.1016/j.pharmthera.2014.11.011 10.1039/C9CC01330J 10.1016/j.ejmech.2021.114044 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-023-31849-5 |
| DatabaseName | SpringerOpen Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest - Health & Medical Complete保健、医学与药学数据库 ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Science Journals Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 4877 |
| ExternalDocumentID | oai_doaj_org_article_c60bbd7986a74112a7050396ee564b5d 10_1038_s41598_023_31849_5 36966194 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: The Open Project of Central Nervous System Drug Key Laboratory of Sichuan Province grantid: 210018-01SZ – fundername: ; grantid: 210018-01SZ |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ADBBV ADRAZ AENEX AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RIG RNT RNTTT RPM SNYQT UKHRP CGR CUY CVF ECM EIF NPM AAYXX AFPKN CITATION 7XB 8FK K9. PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c541t-80133c77178098371733d3ea2341230d46c8edc6c7ac3ab4e0b679531a6d90123 |
| IEDL.DBID | RPM |
| ISSN | 2045-2322 |
| IngestDate | Tue Oct 22 15:15:48 EDT 2024 Tue Sep 17 21:34:34 EDT 2024 Tue Aug 27 04:27:09 EDT 2024 Thu Oct 10 22:50:01 EDT 2024 Fri Aug 23 01:49:51 EDT 2024 Wed Oct 16 00:39:25 EDT 2024 Fri Oct 11 20:48:13 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-80133c77178098371733d3ea2341230d46c8edc6c7ac3ab4e0b679531a6d90123 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039877/ |
| PMID | 36966194 |
| PQID | 2790694503 |
| PQPubID | 2041939 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c60bbd7986a74112a7050396ee564b5d pubmedcentral_primary_oai_pubmedcentral_nih_gov_10039877 proquest_miscellaneous_2791368787 proquest_journals_2790694503 crossref_primary_10_1038_s41598_023_31849_5 pubmed_primary_36966194 springer_journals_10_1038_s41598_023_31849_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-03-25 |
| PublicationDateYYYYMMDD | 2023-03-25 |
| PublicationDate_xml | – month: 03 year: 2023 text: 2023-03-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | SameemBSaeediMMahdaviMShafieeAA review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's diseaseEur. J. Med. Chem.201728332345110.1016/j.ejmech.2016.10.060 LuTDiscovery, biological evaluation and molecular dynamic simulations of butyrylcholinestrase inhibitors through structure-based pharmacophore virtual screeningFuture Med. Chem.202113976978410.4155/fmc-2020-032533759552 LineweaverHBurkDThe determination of enzyme dissociation constantsJ. Am. Chem. Soc19345636586661:CAS:528:DyaA2cXisF2ltg%3D%3D10.1021/ja01318a036 LuDDesign, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer’s disease EurJ. Med. Chem.20222431:CAS:528:DC%2BB38XitlGmur7M10.1016/j.ejmech.2022.114729 SaxenaARedmanAJiangXLockridgeODoctorBDifferences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesteraseBiochemistry19973614642146511:CAS:528:DyaK2sXnt1SgsbY%3D10.1021/bi971425+9398183 JiangYGaoHPharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer's diseasePhytomedicine2019542782901:CAS:528:DC%2BC1cXitV2qt7zI10.1016/j.phymed.2018.09.19930668379 BaruahIBorgohainGBinding interaction of a potential statin with β-lactoglobulin: An in silico approachJ. Mol. Graph. Model.20221111:CAS:528:DC%2BB3MXisFOhsrrF10.1016/j.jmgm.2021.10807734826718 MacdonaldIRMartinERosenberryTLDarveshSProbing the peripheral site of human butyrylcholinesteraseBiochemistry20125136704670531:CAS:528:DC%2BC38Xht1Wku7nE10.1021/bi300955k22901043 Gauthier, S., Webster, C., Servaes, S., Morais, J. A. & Rosa-Neto, P. World Alzheimer report 2022: Life after diagnosis: Navigating treatment, care and support (2022). ManoharanIBoopathyRDarveshSLockridgeOA medical health report on individuals with silent butyrylcholinesterase in the Vysya community of IndiaClin. Chim. Acta.20073781281351:CAS:528:DC%2BD2sXit1Kis7w%3D10.1016/j.cca.2006.11.00517182021 SharmaPComprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategiesProg. Neurobiol.201917453891:CAS:528:DC%2BC1MXksFajsQ%3D%3D10.1016/j.pneurobio.2018.12.00630599179 AllenTWAndersenOSRouxBOn the importance of atomic fluctuations, protein flexibility, and solvent in ion permeationJ. Gen. Physiol200412466796901:CAS:528:DC%2BD2MXjt1Ontg%3D%3D10.1085/jgp.200409111155723472234034 Gentry, M. & Doctor, B. Alignment of amino acid sequences of acetylcholinesterases and butyrylcholinesterases. In Cholinesterases: Structure, Function, Mechanism, Genetics and Cell Biology, American Chemical Society, ACS Conference Proceedings, 394–398 (1991). KufarevaIAbagyanRMethods of protein structure comparisonMethods Mol. Biol.201185723125710.1007/978-1-61779-588-6_10 DarveshSHopkinsDADifferential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamusJ. Comp. Neurol.2003463125431:CAS:528:DC%2BD3sXmsFCgt7Y%3D10.1002/cne.1075112811800 McHardySFWangHLMcCowenSVValdezMCRecent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012–2015)Expert Opin. Ther. Pat.20172744554761:CAS:528:DC%2BC2sXhtFeisLk%3D10.1080/13543776.2017.127257127967267 GreigNHSelective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodentProc. Natl. Acad. Sci. USA.20051024717213172182005PNAS..10217213G1:CAS:528:DC%2BD2MXht1yksLfE10.1073/pnas.0508575102162758991288010 LiBDuysenEGCarlsonMLockridgeOThe butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiencyJ. Pharmacol. Exp. Ther.2008324114611541:CAS:528:DC%2BD1cXivVajsb8%3D10.1124/jpet.107.13333018056867 MedenATryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer’s diseaseChem. Commun.201955376537681:CAS:528:DC%2BC1MXktlemsbY%3D10.1039/C9CC01330J PajouheshHLenzGRMedicinal chemical properties of successful central nervous system drugsNeuroRx20052454155310.1602/neurorx.2.4.541164893641201314 LiuDDesign, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's diseaseEur. J. Med. Chem.20222291:CAS:528:DC%2BB3MXivVSms7rP10.1016/j.ejmech.2021.11404434923430 Furukawa-HibiYButyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-b peptide in miceBehav. Brain Res.201122512222291:CAS:528:DC%2BC3MXhtFKjurrE10.1016/j.bbr.2011.07.035218200134979006 RadicZPickeringNAVellomDCCampSTaylorPThree distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitorsBiochemistry1993324512074120841:CAS:528:DyaK3sXmsVCgtr4%3D10.1021/bi00096a0188218285 JouanneMRaultSVoisin-ChiretASTau protein aggregation in Alzheimer’s disease: an attractive target for the development of novel therapeutic agentsEur. J. Med. Chem.20171391531671:CAS:528:DC%2BC2sXhtlSls7fE10.1016/j.ejmech.2017.07.07028800454 NaZA multiscale screening strategy for the identification of novel xanthine oxidase inhibitors based on the pharmacological features of febuxostat analoguesNew J. Chem.2022466549655910.1039/D2NJ00115B FrancisPTPalmerAMSnapeMWilcockGKThe cholinergic hypothesis of Alzheimer’s disease: a review of progressJ. Neurol. Neurosurg. Psychiatry.1999661371471:STN:280:DyaK1M7mvVKnuw%3D%3D10.1136/jnnp.66.2.137100710911736202 ChierritoTPCChameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitorsEur. J. Med. Chem.20181454314441:CAS:528:DC%2BC1cXosFKgug%3D%3D10.1016/j.ejmech.2018.01.00729335209 SalmasoVMoroSBridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overviewFront. Pharmacol.2018992310.3389/fphar.2018.00923301861666113859 JomovKVondrakovaDLawsonMValkoMMetals, oxidative stress and neurodegenerative disordersMol. Cell. Biochem.20103459110410.1007/s11010-010-0563-x LockridgeOReview of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic usesPharmacol. Ther.201514834461:CAS:528:DC%2BC2cXhvFOgsb%2FK10.1016/j.pharmthera.2014.11.01125448037 FerreiraLLGAndricopuloADADMET modeling approaches in drug discoveryDrug Discov. Today.2019245115711651:CAS:528:DC%2BC1MXmtVCnt7k%3D10.1016/j.drudis.2019.03.01530890362 IR Macdonald (31849_CR14) 2012; 51 Y Jiang (31849_CR23) 2019; 54 NH Greig (31849_CR10) 2005; 102 TPC Chierrito (31849_CR18) 2018; 145 SF McHardy (31849_CR5) 2017; 27 B Li (31849_CR11) 2008; 324 O Lockridge (31849_CR13) 2015; 148 H Lineweaver (31849_CR22) 1934; 56 B Sameem (31849_CR6) 2017; 28 I Manoharan (31849_CR12) 2007; 378 A Saxena (31849_CR8) 1997; 36 Z Na (31849_CR29) 2022; 46 I Baruah (31849_CR28) 2022; 111 M Jouanne (31849_CR3) 2017; 139 H Pajouhesh (31849_CR31) 2005; 2 Y Furukawa-Hibi (31849_CR9) 2011; 225 K Jomov (31849_CR4) 2010; 345 31849_CR1 P Sharma (31849_CR24) 2019; 174 31849_CR7 T Lu (31849_CR17) 2021; 13 LLG Ferreira (31849_CR30) 2019; 24 PT Francis (31849_CR2) 1999; 66 D Lu (31849_CR21) 2022; 243 A Meden (31849_CR19) 2019; 55 TW Allen (31849_CR27) 2004; 124 D Liu (31849_CR20) 2022; 229 Z Radic (31849_CR15) 1993; 32 S Darvesh (31849_CR16) 2003; 463 V Salmaso (31849_CR25) 2018; 9 I Kufareva (31849_CR26) 2011; 857 |
| References_xml | – volume: 463 start-page: 25 issue: 1 year: 2003 ident: 31849_CR16 publication-title: J. Comp. Neurol. doi: 10.1002/cne.10751 contributor: fullname: S Darvesh – volume: 124 start-page: 679 issue: 6 year: 2004 ident: 31849_CR27 publication-title: J. Gen. Physiol doi: 10.1085/jgp.200409111 contributor: fullname: TW Allen – volume: 32 start-page: 12074 issue: 45 year: 1993 ident: 31849_CR15 publication-title: Biochemistry doi: 10.1021/bi00096a018 contributor: fullname: Z Radic – ident: 31849_CR7 – volume: 51 start-page: 7046 issue: 36 year: 2012 ident: 31849_CR14 publication-title: Biochemistry doi: 10.1021/bi300955k contributor: fullname: IR Macdonald – volume: 56 start-page: 658 issue: 3 year: 1934 ident: 31849_CR22 publication-title: J. Am. Chem. Soc doi: 10.1021/ja01318a036 contributor: fullname: H Lineweaver – volume: 2 start-page: 541 issue: 4 year: 2005 ident: 31849_CR31 publication-title: NeuroRx doi: 10.1602/neurorx.2.4.541 contributor: fullname: H Pajouhesh – volume: 66 start-page: 137 year: 1999 ident: 31849_CR2 publication-title: J. Neurol. Neurosurg. Psychiatry. doi: 10.1136/jnnp.66.2.137 contributor: fullname: PT Francis – volume: 243 year: 2022 ident: 31849_CR21 publication-title: J. Med. Chem. doi: 10.1016/j.ejmech.2022.114729 contributor: fullname: D Lu – volume: 174 start-page: 53 year: 2019 ident: 31849_CR24 publication-title: Prog. Neurobiol. doi: 10.1016/j.pneurobio.2018.12.006 contributor: fullname: P Sharma – volume: 324 start-page: 1146 year: 2008 ident: 31849_CR11 publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.107.133330 contributor: fullname: B Li – volume: 54 start-page: 278 year: 2019 ident: 31849_CR23 publication-title: Phytomedicine doi: 10.1016/j.phymed.2018.09.199 contributor: fullname: Y Jiang – ident: 31849_CR1 – volume: 139 start-page: 153 year: 2017 ident: 31849_CR3 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2017.07.070 contributor: fullname: M Jouanne – volume: 345 start-page: 91 year: 2010 ident: 31849_CR4 publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-010-0563-x contributor: fullname: K Jomov – volume: 36 start-page: 14642 year: 1997 ident: 31849_CR8 publication-title: Biochemistry doi: 10.1021/bi971425+ contributor: fullname: A Saxena – volume: 9 start-page: 923 year: 2018 ident: 31849_CR25 publication-title: Front. Pharmacol. doi: 10.3389/fphar.2018.00923 contributor: fullname: V Salmaso – volume: 378 start-page: 128 year: 2007 ident: 31849_CR12 publication-title: Clin. Chim. Acta. doi: 10.1016/j.cca.2006.11.005 contributor: fullname: I Manoharan – volume: 28 start-page: 332 year: 2017 ident: 31849_CR6 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2016.10.060 contributor: fullname: B Sameem – volume: 857 start-page: 231 year: 2011 ident: 31849_CR26 publication-title: Methods Mol. Biol. doi: 10.1007/978-1-61779-588-6_10 contributor: fullname: I Kufareva – volume: 24 start-page: 1157 issue: 5 year: 2019 ident: 31849_CR30 publication-title: Drug Discov. Today. doi: 10.1016/j.drudis.2019.03.015 contributor: fullname: LLG Ferreira – volume: 145 start-page: 431 year: 2018 ident: 31849_CR18 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2018.01.007 contributor: fullname: TPC Chierrito – volume: 111 year: 2022 ident: 31849_CR28 publication-title: J. Mol. Graph. Model. doi: 10.1016/j.jmgm.2021.108077 contributor: fullname: I Baruah – volume: 46 start-page: 6549 year: 2022 ident: 31849_CR29 publication-title: New J. Chem. doi: 10.1039/D2NJ00115B contributor: fullname: Z Na – volume: 102 start-page: 17213 issue: 47 year: 2005 ident: 31849_CR10 publication-title: Proc. Natl. Acad. Sci. USA. doi: 10.1073/pnas.0508575102 contributor: fullname: NH Greig – volume: 27 start-page: 455 issue: 4 year: 2017 ident: 31849_CR5 publication-title: Expert Opin. Ther. Pat. doi: 10.1080/13543776.2017.1272571 contributor: fullname: SF McHardy – volume: 225 start-page: 222 issue: 1 year: 2011 ident: 31849_CR9 publication-title: Behav. Brain Res. doi: 10.1016/j.bbr.2011.07.035 contributor: fullname: Y Furukawa-Hibi – volume: 13 start-page: 769 issue: 9 year: 2021 ident: 31849_CR17 publication-title: Future Med. Chem. doi: 10.4155/fmc-2020-0325 contributor: fullname: T Lu – volume: 148 start-page: 34 year: 2015 ident: 31849_CR13 publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2014.11.011 contributor: fullname: O Lockridge – volume: 55 start-page: 3765 year: 2019 ident: 31849_CR19 publication-title: Chem. Commun. doi: 10.1039/C9CC01330J contributor: fullname: A Meden – volume: 229 year: 2022 ident: 31849_CR20 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2021.114044 contributor: fullname: D Liu |
| SSID | ssj0000529419 |
| Score | 2.4626307 |
| Snippet | Alzheimer’s disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective therapeutic target... Alzheimer's disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective therapeutic target... Abstract Alzheimer’s disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective... Abstract Alzheimer’s disease (AD) is the most common type of age-related dementia. Inhibition of butyrylcholinesterase (BChE) emerge as an effective... |
| SourceID | doaj pubmedcentral proquest crossref pubmed springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 4877 |
| SubjectTerms | 631/154 631/154/309 631/154/309/2420 Acetamides - pharmacology Acetamides - therapeutic use Acetylcholinesterase - metabolism Age Alzheimer Disease - drug therapy Alzheimer's disease Amides - therapeutic use Bioassays Butyrylcholinesterase - metabolism Cholinesterase Inhibitors - chemistry Dementia disorders Humanities and Social Sciences Humans Hydrogen bonding Molecular Docking Simulation Molecular dynamics Molecular Structure multidisciplinary Neurodegenerative diseases Science Science (multidisciplinary) Structure-Activity Relationship Therapeutic targets |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOilNE0fTtKiQG-tiS3Jehzb0hAKzaUN5Cb0CjG03hB7C_vvOyN5N9k-6CVXSzJjzWge1sw3hLxh3PugtKl9ABUIFk_X3qfLWjmtnfYmtDmb8MuZPD0Xny-6izutvjAnrMADl407DrLxPiqjpQPj1zKnEMHEyJQ6KXwXs_ZtuzvBVEH1Zka0Zq6Sabg-HsFSYTUZw3IyLUzdbVmiDNj_Ny_zz2TJ325MsyE6eUIezx4kfV8o3yUP0vCUPCw9JVd7ZPl1NYBTN_YjdUOkBWQJOUFvgb3p4pKOoDFKmkCkLqTJ_ehjohEE8mfGAoflI71eTJhNBIv9clrdrL6jssREeaBxTLQfrnrfY7-eZ-T85NO3j6f13FuhDp1oJzRMnAcFwZxuDASpreI88uQYWDWISqKQQcM3y6Bc4M6L1HipDBxYJ6NBP-w52RkWQ3pJqI8iNIaHGDsvgmtM0Ia1EQNBqcE9qMjb9T7b6wKhYfPVN9e2cMUCV2zmiu0q8gFZsZmJ8Nf5AQiFnYXC_k8oKnK4ZqSdz-RomTJY5QsTK3K0GYbThFckbkiLZZ7TcqlBi1XkReH7hhLsfIj_fCqityRii9TtkaG_yojdLZZAawUvfbcWnlu6_r0X-_exFwfkEUOpb3jNukOyM90s0ytwpCb_Op-ZX4OOGpA priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1ba9UwOOiG4It4tzolgm9a1jZpLk-yjY0hOEQd7C3kNleY7fG0Rzj_3u9Le87hOOdrk5Qk3zXflZB3FXPOS6Vz54EFgsRTuXPxMpdWKauc9mWKJvx8Jk7P-aeL-mIyuPVTWOWKJyZGHTqPNvL9SmrM0awL9nH2K8euUehdnVpo3CW7VcnRTbt7eHz25evayoJ-LF7qKVumYGq_B4mFWWUVppUprvN6SyKlwv3_0jZvBk3-5TlNAunkIXkwaZL0YAT9I3Into_JvbG35PIJWXxbtqDc9U1PbRvoWGwJIUI3Bb5pd0l74BxjuECg1sfB_mxCpAEQ83eqCQ7LezrrBowqgsVuMSzny2tkmhgwD3vsI23aq8Y12LfnKTk_Of5-dJpPPRZyX_NyQAHFmJfwqFOFhsdqKRkLLNoKpBu8TgIXXsGZhZfWM-t4LJyQGgjXiqBRH3tGdtqujS8IdYH7QjMfQu24t4X2SldlwAehUKAmZOT96p7NbCylYZILnCkzQsUAVEyCiqkzcoigWM_EMtjpQzf_YSaqMl4UzgWplbCgGZWVlVjeRosYa8FdHTKytwKkmWizNxtMysjb9TBQFbpKbBu7RZpTMqGAm2Xk-Qj39U6wAyLafjKitjBia6vbI21zlSp3l5gKrST89MMKeTb7uv0uXv7_GK_IfVDj6jGIeI_sDPNFfA2q0uDeTPTwB174FB8 priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9QwDI_GEBIviG8KAwWJNyi0SZqPB4QAMU1I4wVO2luVr7FKWzuuPUT_e-y0d9PBIfHaJJUb27Hd2D8T8oJx57zSJncejkCweDp3Lp7mympttTO-TNmEx1_k0UJ8PqlO9si63dG8gf3O0A77SS2W569__RjfgcK_nUrG9ZsejBAWijGsFNPC5NU1cp0JLlDij2d3f8L6ZkaUZq6d2b10yz4lGP9dvuffKZR_3KMm83R4m9ya_Ur6fhKEO2QvtnfJjanT5HiPrL6OLbh6fdNT2wY6QS8hf-gV3DftTmkP58iUPBCo9XGwF02INICY_kwI4bC8p5fdgDlGsNithnE5nuMuYvo80NhH2rRnjWuwi899sjj89O3jUT53XMh9JcoBzRXnXkGIpwsDoWupOA88Wga2DmKVIKTX8M3SK-u5dSIWTioDamxlMOidPSD7bdfGR4S6IHxhuA-hcsLbwnhtWBkwPJQanIaMvFzvc305AWvU6UKc63riSg1cqRNX6iojH5AVm5kIip0edMvv9axjtZeFc0EZLS34SSWzCsFujIyxksJVISMHa0bWa0GrmTJY-wsTM_J8Mww6hhcnto3dKs0pudRwtmXk4cT3DSXYDxH_BGVEb0nEFqnbI21zlnC8SyyM1gpe-motPFd0_XsvHv8HnU_ITYZCXfCcVQdkf1iu4lPwngb3LKnEbyo8GBE priority: 102 providerName: Scholars Portal – databaseName: SpringerOpen dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Na9VAEB-0IngRvxutsoI3DSbZ7NdRH5Yi6EULvS37VRrQvNLkCe-_d2aT90q0HrxmP9jszOzM7sz8BuBNw70PSpvSBzwCUePp0vt0XiqntdPehDpHE375Kk9O289n4myGyaFcmIX_nuv3AyoYSgJrKAtMt6YUt-GOwAmIg1dytX9PIY9VW5s5L-bmoQvdkyH6b7Ir_w6P_MNHmlXP8QO4P9uM7MNE5IdwK_WP4O5URXL7GDbftj2acUM3MNdHNsEq0d6zayhvtj5nA54RU2BAZC6k0f3sYmIRWfBXRv_G4QO7XI8UP4SD_WbcXm1_0PFIofG4xiGxrr_ofEcVep7A6fGn76uTcq6mUAbR1iOpIs6DwuubrgxeS2vFeeTJNajH8B4SWxk0_rMMygXufJsqL5VBEXUyGrK8nsJBv-7TITAf21AZHmIUvg2uMkGbpo509ZMaDYIC3u722V5OoBk2O7u5thNVLFLFZqpYUcBHIsW-JwFe5w_IB3aWHxtk5X1URkuHNlDdOEVANkamJGTrRSzgaEdIO0vhYBtlKK8XOxbwet-M8kNOEden9Sb3qbnUeG4V8Gyi-34lVOuQXnkK0AuOWCx12dJ3Fxmju6akZ61w0nc75rle17_34vn_dX8B9xri74qXjTiCg_Fqk16ikTT6V1k6fgPSGgux priority: 102 providerName: Springer Nature |
| Title | Synthesis and biological evaluation of substituted acetamide derivatives as potential butyrylcholinestrase inhibitors |
| URI | https://link.springer.com/article/10.1038/s41598-023-31849-5 https://www.ncbi.nlm.nih.gov/pubmed/36966194 https://www.proquest.com/docview/2790694503 https://search.proquest.com/docview/2791368787 https://pubmed.ncbi.nlm.nih.gov/PMC10039877 https://doaj.org/article/c60bbd7986a74112a7050396ee564b5d |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB6SlEIvpe8oTc0WemsVS1ppH8fGJISCQ2gb8E3sK40glowlF_zvM7uynLqPSy8CSSs02pnZmdHOfAPwIaNaGy5krA0ugWjxRKy1u4m5EkIJLU0asgmnl-ziOv8yK2Z7wIZamJC0b3R1Ut_NT-rqNuRWLuZmPOSJja-mk9RXlArOx_uwzyn9JUbvEb0zmadyUyGTUDFu0Ur5SrLMl5KJXMa-X41vZOdD-B2DFHD7_-Zs_pkz-dvGabBH58_g6caRJJ97gp_DnqtfwOO-teT6Jay-rWv07dqqJaq2pMda8gwhD_jepLkhLS4cfbaAJcq4Ts0r64hFufwZIMHx8ZYsms4nFeHDetWtl-s7v2b6fHmksXWkqm8rXfm2Pa_g-vzs--Qi3rRYiE2Rp523T5QajjGdSCTGqilOp6VOZWjcMDixOTMCv5kZrgxVOneJZlyi3ipmpXfHXsNB3dTuEIi2uUkkNdYWOjcqkUbILLU-HmQCvYQIPg7zXC56JI0y7IBTUfYMKpFBZWBQWURw6lmxHelRsMOFZvmj3MhCaViiteVSMIWOUZop7tFtJHOuYLkubATHAyPLjWq2ZcalL_bFgRG8395GpfI7Jap2zSqMSSkTuJhF8Kbn-5aSQW4iEDsSsUPq7h2U4wDcPchtBJ8G4Xmg699zcfT_b3oLTzIv9gmNs-IYDrrlyr1DL6rTI1SdGR_Bo9Ozy6uveDZhk1H4I4HHaS5GQanuAS2hIVA |
| link.rule.ids | 230,315,733,786,790,870,891,2115,12083,21416,24346,27955,27956,31752,31753,33777,33778,41153,42222,43343,43838,51609,53825,53827,74100,74657 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3JbtQw1IIiBBfETqCAkbhB1CR2vJwQIKoB2l5opd4sb6WRIBkmGaT5e95zMjMatmtsR7bf6rcS8rJiznmpdO48sECQeCp3Ll7k0iplldO-TNGExydidsY_ndfnk8Gtn8Iq1zwxMerQebSRH1RSY45mXbA38x85do1C7-rUQuMqucYZ44jn8lxubCzoxeKlnnJlCqYOepBXmFNWYVKZ4jqvd-RRKtv_N13zz5DJ3_ymSRwd3ia3Jj2Svh0Bf4dcie1dcn3sLLm6R5ZfVi2odn3TU9sGOpZaQnjQbXlv2l3QHvjGGCwQqPVxsN-bEGkAtPyZKoLD8p7OuwFjimCxWw6rxeobskwMl4c99pE27WXjGuzac5-cHX44fT_Lpw4Lua95OaB4YsxLeNKpQsNTtZSMBRZtBbIN3iaBC6_gzMJL65l1PBZOSA1ka0XQqI09IHtt18ZHhLrAfaGZD6F23NtCe6WrMuBzUChQEjLyan3PZj4W0jDJAc6UGaFiAComQcXUGXmHoNjMxCLY6UO3-GommjJeFM4FqZWwoBeVlZVY3EaLGGvBXR0ysr8GpJkoszdbPMrIi80w0BQ6Smwbu2WaUzKhgJdl5OEI981OsP8hWn4yonYwYmeruyNtc5nqdpeYCK0k_PT1Gnm2-_r3XTz-_zGekxuz0-Mjc_Tx5PMTcrNC3C5YXtX7ZG9YLONTUJoG9yxRxi_U2xWn |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3JjtMw1IJBIC6IdQgMYCRuEDWJEy8nxFYN2wgJRurN8lYmEpN0mhSpf897TtqqbNfYjp79VvtthDwrmLVOSJVaByIQNJ5MrQ3zVBgpjbTK5TGa8PMJPz4tP8yq2Rj_1I1hlRuZGAW1bx2-kU8KoTBHs8rYZD6GRXx5O325uEixgxR6Wsd2GpfJFdCSGbZxEDOxfW9Bj1aZqzFvJmNy0oHuwvyyAhPMZKnSak83xRL-f7M7_wyf_M2HGlXT9Ca5MdqU9NVABLfIpdDcJleHLpPrO2T1dd2AmdfVHTWNp0PZJcQN3ZX6pu2cdiBDhsABT40LvTmvfaAeSPRnrA4Oyzu6aHuML4LFdtWvl-sfKD4xdB5g7AKtm7Pa1tjB5y45nb779uY4HbstpK4q8x5VFWNOwPVOZgqurblgzLNgCtBzcE_xJXcS9sydMI4ZW4bMcqGAhQ33Ci2ze-SgaZtwn1DrS5cp5ryvbOlMppxURe7xasglGAwJeb45Z70Yimro6AxnUg9Y0YAVHbGiq4S8RlRsZ2JB7PihXX7XI39pxzNrvVCSG8B-XhiBhW4UD6Hipa18Qo42iNQjl3Z6R1MJebodBv5Cp4lpQruKc3LGJci1hBwOeN9Cgr0Q8RUoIXKPIvZA3R9p6rNYwzvHpGgp4KcvNsSzg-vfZ_Hg_9t4Qq4BU-hP708-PiTXCyTtjKVFdUQO-uUqPAL7qbePI2P8AsWtGdM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synthesis+and+biological+evaluation+of+substituted+acetamide+derivatives+as+potential+butyrylcholinestrase+inhibitors&rft.jtitle=Scientific+reports&rft.au=Yu%2C+Dehong&rft.au=Yang%2C+Can&rft.au=Liu%2C+Yi&rft.au=Lu%2C+Tao&rft.date=2023-03-25&rft.eissn=2045-2322&rft.volume=13&rft.issue=1&rft.spage=4877&rft.epage=4877&rft_id=info:doi/10.1038%2Fs41598-023-31849-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |